Akagera Medicines is developing novel liposomal formulations of antibacterial drugs to treat tuberculosis. The company was founded in 2018 in Kigali, Rwanda. It is well-funded, majority-owned by the people of Rwanda, incorporated as a Delaware corporation, and has laboratories in Boston and San Francisco. Board members and advisors include Ambassador Dr. Albrecht Conze, Dr. Paul Farmer, Dr. Donald Kaberuka, and Dr. Anne Lenaerts. Akagera Medicines intends (if toxicology and Proof of Concept efficacy studies go as anticipated) to begin IND-enabling studies in Q4 2020. The moral purpose of Akagera Medicines is to create medicines that lead to a world free of tuberculosis (TB), humankind’s greatest killer. This means improving efficacy, shortening the duration of treatment, optimizing drug/drug interaction, eliminating toxicity, and lowering the costs to patients and to society. Our Goals • to initiate clinical trials in humans in 2022; • to reduce the global incidence of TB deaths by 80% in the next decade; • to eradicate the multi-drug resistant (MDR) form of TB; • to explore the high probability that Akagera Medicines' approach will work to create treatments and vaccines in other infectious diseases like MRSA, Malaria, and HIV; • and to ensure that those treatments could be created, tested, and manufactured in the heart of Africa.